Antibacterial prophylaxis in patients with cancer and neutropenia [6]

New England Journal of Medicine

Volumn 354, Issue 1, 2006, Pages 90-

  Freifeld, Alison G ^a   Sepkowitz, Kent A ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CANCER; CLINICAL TRIAL; DRUG COST; DRUG SAFETY; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; LETTER; LEUKEMIA; NEUTROPENIA; PRIORITY JOURNAL; SOLID TUMOR; STEM CELL TRANSPLANTATION;

EID: 30044438252     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc052613     Document Type: Letter

References (4)

1. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977-87.
2. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988-98.
3. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-95.
4. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.